WEST LAFAYETTE, Ind., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that Mike Sherman, chief financial and operating officer of Endocyte, will present at the 2014 Credit Suisse Healthcare Conference on Tuesday, Nov.11, at 8:00 a.m. MT (10:00 a.m. ET). The conference will be held at The Biltmore Hotel in Phoenix, Arizona.
A live audio webcast of the Company's presentation can be accessed at http://cc.talkpoint.com/cred001/111114a_jw/?entity=23_MSTQHBD or by visiting "Events & Presentations" under the Investors & News section of Endocyte's website at www.endocyte.com. The webcast will be archived shortly after the live event and a replay will be available on the Company's website for 90 days following the conference.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company's SMDCs actively target receptors that are expressed or over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly potent drugs into these cells. The companion imaging agents are designed to identify patients whose disease expresses the molecular target of the therapy and who therefore may be more likely to benefit from treatment. For more information, visit http://www.endocyte.com.
CONTACT: Stephanie Ascher, Stern Investor Relations, Inc.
(212) 362-1200, stephanie@sternir.com
